| Literature DB >> 35966629 |
Yang Yang1, Li-Chun Wang1, Xin-Yang Yu2, Xiao-Fei Zhang1, Zhong-Qing Yang2, Yang-Zi Zheng2, Bin-Yan Jiang2, Lei Chen1.
Abstract
Background: Fournier's gangrene (FG) is a rare life-threatening form of necrotizing fasciitis. The risk factors for septic shock in patients with FG are unclear. This study aimed to identify potential risk factors and develop a prediction model for septic shock in patients with FG.Entities:
Keywords: Fournier’s gangrene; nomogram; risk prediction; sepsis; septic shock
Year: 2022 PMID: 35966629 PMCID: PMC9368829 DOI: 10.1093/gastro/goac038
Source DB: PubMed Journal: Gastroenterol Rep (Oxf)
Figure 1.Flow chart showing the patient enrolment process
Demographic and clinical characteristics of patients with Fournier’s gangrene
| Characteristic | Total ( | Septic shock group ( | Non-septic shock group ( |
|
|---|---|---|---|---|
| Age, years | 49.6 ± 14.9 | 49.5 ± 16.5 | 49.6 ± 14.5 | 0.975 |
| Male, | 101 (89.4) | 21 (87.5) | 80 (89.9) | 0.716 |
| BMI, kg/m2 | 24.7 ± 4.0 | 24.5 ± 3.3 | 24.7 ± 4.2 | 0.834 |
| Co-morbidities, | ||||
| Pulmonary disease | 1 (0.9) | 0 (0) | 1 (1.1) | 0.619 |
| Hypertension | 25 (22.1) | 5 (20.8) | 20 (22.5) | 0.868 |
| Diabetes mellitus | 63 (55.8) | 12 (50.0) | 51 (57.3) | 0.527 |
| Heart disease | 5 (4.4) | 2 (8.3) | 3 (3.4) | 0.301 |
| Acute renal injury | 6 (5.3) | 2 (8.3) | 4 (4.5) | 0.464 |
| Neurological disorder | 3 (2.7) | 0 (0) | 3 (3.4) | 0.371 |
| Liver disease | 9 (8.0) | 1 (4.2) | 8 (9.0) | 0.445 |
| Hyperlipidemia | 2 (1.8) | 1 (4.2) | 1 (1.1) | 0.325 |
| Immunosuppression | 4 (3.5) | 1 (4.2) | 3 (3.4) | 0.861 |
| Malignancy | 8 (7.1) | 3 (12.5) | 5 (5.6) | 0.249 |
| Smoking and/or alcoholism, | 11 (9.7) | 1 (4.2) | 10 (11.2) | 0.305 |
| Vital signs | ||||
| T, °C | 37.1 ± 0.9 | 37.7 ± 1.2 | 36.9 ± 0.7 | 0.001 |
| P, bpm | 93.5 ± 18.0 | 99.5 ± 22.7 | 91.8 ± 16.3 | 0.063 |
| RR, bpm | 20.1 ± 3.5 | 20.7 ± 5.9 | 19.9 ± 2.5 | 0.551 |
| SBP, mmHg | 123.9 ± 18.5 | 117.5 ± 24.9 | 125.7 ± 16.1 | 0.056 |
| DBP, mmHg | 75.2 ± 11.5 | 70.1 ± 14.5 | 76.6 ± 10.2 | 0.050 |
| MAP, mmHg | 91.5 ± 12.7 | 85.9 ± 16.9 | 92.9 ± 11.0 | 0.064 |
| Laboratory examinations | ||||
| WBC count, × 109/L | 14.7 ± 6.8 | 14.0 ± 6.9 | 14.9 ± 6.8 | 0.582 |
| Neutrophil percentage | 0.80 ± 0.09 | 0.82 ± 0.08 | 0.79 ± 0.09 | 0.153 |
| PLT, × 109/L | 263.8 ± 140.2 | 179.8 ± 103.8 | 286.4 ± 140.5 | 0.001 |
| Hb, g/L | 117.3 ± 24.9 | 110.1 ± 29.0 | 119.3 ± 23.5 | 0.109 |
| HCT | 0.34 ± 0.06 | 0.32 ± 0.07 | 0.35 ± 0.06 | 0.024 |
| Na+, mmol/L | 136.6 ± 5.6 | 138.9 ± 9.4 | 136.0 ± 4.0 | 0.056 |
| K+, mmol/L | 3.8 ± 0.5 | 3.8 ± 0.5 | 3.9 ± 0.5 | 0.622 |
| Lymphocyte, × 109/L | 1.3 ± 0.7 | 1.2 ± 0.6 | 1.4 ± 0.7 | 0.287 |
| PT, s | 14.1 ± 2.5 | 15.5 ± 3.7 | 13.7 ± 2.0 | 0.026 |
| APTT, s | 32.0 ± 11.2 | 32.3 ± 6.6 | 31.9 ± 12.2 | 0.505 |
| Glucose, mmol/L | 11.3 ± 7.1 | 9.9 ± 6.0 | 11.7 ± 7.4 | 0.305 |
| Cr, μmol/L | 91.4 ± 57.4 | 98.8 ± 49.2 | 89.4 ± 59.5 | 0.446 |
| ALB, g/L | 29.3 ± 7.3 | 24.9 ± 7.3 | 30.4 ± 6.9 | 0.001 |
| TBIL, μmol/L | 23.0 ± 35.4 | 46.9 ± 67.5 | 16.5 ± 14.5 | 0.030 |
| LRINEC score | 4.5 ± 2.4 | 5.5 ± 1.9 | 4.2 ± 2.5 | 0.137 |
| CT/MRI pneumatosis, | 64 (56.6) | 20 (83.3) | 44 (49.4) | 0.003 |
ALB, albumin; APTT, activated partial thromboplastin time; BMI, body mass index; Cr, creatinine; CT/MRI, computed tomography/magnetic resonance images; DBP, diastolic blood pressure; Hb, haemoglobin; HCT, hematocrit; LRINEC, Laboratory Risk Indicator for Necrotizing Fasciitis; MAP, mean arterial pressure; P, pulse; PLT, platelet count; PT, prothrombin time; RR, respiratory rate; SBP, systolic blood pressure; T, temperature; TBIL, total bilirubin; WBC, white blood cells.
Clinical interventions and findings
| Variable | Total ( | Septic shock group ( | Non-septic shock group ( |
|
|---|---|---|---|---|
| Admission time, | ||||
| Weekdays | 69 (61.1) | 14 (58.3) | 55 (61.8) | 0.757 |
| Weeknights | 21 (18.6) | 3 (12.5) | 18 (20.2) | 0.570 |
| Weekend days | 16 (14.1) | 6 (25.0) | 10 (11.2) | 0.166 |
| Weekend nights | 7 (6.2) | 1 (4.2) | 6 (6.7) | 1.000 |
| Surgery | ||||
| Number of receiving surgical service, | 108 (95.6) | 21 (87.5) | 87 (97.8) | 0.108 |
| Number of surgical debridement | 1.1 ± 0.5 | 1.1 ± 0.8 | 1.2 ± 0.4 | 0.534 |
| Colostomy, | 22 (19.5) | 9 (37.5) | 13 (14.6) | 0.013 |
| Vacuum-assisted closure, | 6 (5.3) | 1 (4.2) | 5 (5.6) | 0.786 |
| Antibiotics | ||||
| Time from admission to antibiotics infusion, hours | 2.4 ± 2.0 | 2.5 ± 2.5 | 2.4 ± 1.8 | 0.830 |
| Types of antibiotics initially used, | ||||
| Second-generation cephalosporins | 19 (16.8) | 3 (12.5) | 16 (18.0) | 0.817 |
| Three-generation cephalosporins | 27 (23.9) | 4 (16.7) | 23 (25.8) | 0.506 |
| Third-generation cephalosporin plus enzyme inhibitor | 42 (37.2) | 9 (37.5) | 33 (37.1) | 0.970 |
| Penicillin plus enzyme inhibitors | 14 (12.3) | 4 (16.7) | 10 (11.2) | 0.713 |
| Carbapenem antibiotics | 11 (9.7) | 4 (16.7) | 7 (7.9) | 0.367 |
| Antibiotic-days during hospital stay, days | 11.5 ± 7.6 | 13.6 ± 9.2 | 10.9 ± 7.0 | 0.180 |
| The use of CRRT, | 6 (5.3) | 5 (20.8) | 1 (1.1) | 0.001 |
| Clinical findings | ||||
| Time from symptoms onset to admission, days | 13.5 ± 18.1 | 9.3 ± 7.5 | 14.7 ± 19.8 | 0.193 |
| Time from admission to surgery, hours | 24.4 ± 35.4 | 21.4 ± 38.9 | 39.1 ± 62.0 | 0.225 |
| ICU stay, days | 1.8 ± 4.1 | 5.7 ± 7.0 | 0.8 ± 1.9 | < 0.001 |
| Hospital length of stay, days | 22.8 ± 16.0 | 22.7 ± 12.3 | 22.8 ± 16.9 | 0.294 |
| In-hospital mortality, | 7 (6.2) | 6 (25.0) | 1 (1.1) | < 0.001 |
CRRT, continuous renal replacement therapy; ICU, intensive care unit.
Figure 2.The AUROCs for selected factors and the ROCs for factors with an AUROC of >0.6. (A) The AUROCs for selected factors. (B) ROCs for selected factors with an AUROC of >0.6. ALB, albumin; APTT, activated partial thromboplastin time; AUROC, area under the receiver-operating characteristic curve; Cr, creatinine; CT/MRI, computed tomography/magnetic resonance images; MAP, mean arterial pressure; P, pulse; PLT, platelet count; PT, prothrombin time; ROC, receiver-operating characteristic curve; SBP, systolic blood pressure; T, temperature; TBIL, total bilirubin.
Figure 3.Sodium and total bilirubin (TBIL) distribution curves and the empirical probability of septic shock. (A) and (B) Marginal distribution of sodium and TBIL. (C) Joint distribution of TBIL and sodium. (D) Empirical probability of sepsis vs log (sodium × TBIL).
Figure 4.ROC for the fitted logistic regression model. (A) ROC of the fitted logistic regression model. (B) ROCs of selected variables. AUC, area under the receiver-operating characteristic curve; CT/MRI, computed tomography/magnetic resonance image; PLT, platelet count; ROC, receiver-operating characteristic curve; T, temperature; TBIL, total bilirubin.
Numbers and proportions of patients who developed complications
| Complication | Non-septic shock group ( | Septic shock group ( |
|
|---|---|---|---|
| Fever | 18 (20.2%) | 13 (54.2%) | 0.002 |
| Thrombocytopenia | 6 (6.7%) | 6 (25.0%) | 0.028 |
| Hyperbilirubinemia | 12 (13.5%) | 11 (45.8%) | 0.001 |
| Hyponatremia | 44 (49.4%) | 7 (29.2%) | 0.077 |
| Hypernatremia | 1 (1.1%) | 4 (16.7%) | 0.006 |
| Hypernatremia and hyperbilirubinemia | 0 (0%) | 2 (8.3%) | 0.044 |
P-value of chi-square test.
Figure 5.Nomogram established for predicting Fournier’s gangrene with septic shock. CT/MRI, computed tomography/magnetic resonance image; PLT, platelet count; T, temperature; TBIL, total bilirubin; Na_TBIL = (Na+ − 135.74) × TBIL.
Coefficients for the selected logistic regression model
| Variable | Estimate | Standard error | z-value | Pr(>|z|) |
|---|---|---|---|---|
| (Intercept) | −37.04 | 13.06 | −2.84 | 0.005 |
| Temperature | 0.96 | 0.35 | 2.75 | 0.006 |
| Platelet count | −0.01 | 0.00 | −2.24 | 0.025 |
| Total bilirubin | −0.56 | 0.30 | −1.84 | 0.066 |
| CT/MRI pneumatosis | 1.94 | 0.74 | 2.63 | 0.009 |
| Na+ × TBIL | 0.00 | 0.00 | 1.87 | 0.062 |
CT/MRI, computed tomography/magnetic resonance imaging; Na+, sodium; TBIL, total bilirubin. Na+ × TBIL, product of the total bilirubin value and the sodium value. Bayesian information criterion: 88.52.
Figure 6.Calibration curve for our internal validation nomogram model